X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (50) 50
index medicus (42) 42
male (28) 28
cardiac & cardiovascular systems (27) 27
female (27) 27
middle aged (27) 27
cardiovascular (24) 24
mortality (22) 22
clopidogrel (20) 20
ticlopidine - analogs & derivatives (18) 18
treatment outcome (16) 16
abridged index medicus (15) 15
aged (15) 15
cardiac patients (14) 14
drug therapy (13) 13
acute coronary syndromes (12) 12
analysis (12) 12
heart attacks (12) 12
prasugrel (12) 12
risk factors (12) 12
percutaneous coronary intervention (11) 11
prognosis (11) 11
systemic sclerosis (11) 11
antiplatelet therapy (10) 10
internal medicine (10) 10
myocardial infarction (10) 10
platelet aggregation inhibitors - therapeutic use (10) 10
cardiology (9) 9
platelet aggregation inhibitors - administration & dosage (9) 9
stents (9) 9
ticlopidine - therapeutic use (9) 9
follow-up studies (8) 8
high platelet reactivity (8) 8
rheumatology (8) 8
ticlopidine - administration & dosage (8) 8
transluminal angioplasty (8) 8
adult (7) 7
bleeding (7) 7
care and treatment (7) 7
coronary heart disease (7) 7
heart attack (7) 7
medicine, general & internal (7) 7
meta-analysis (7) 7
metaanalysis (7) 7
patient outcomes (7) 7
platelet function testing (7) 7
platelet function tests (7) 7
prospective studies (7) 7
risk assessment (7) 7
stent thrombosis (7) 7
acute coronary syndrome (6) 6
acute coronary syndrome - therapy (6) 6
angioplasty (6) 6
cardiology and cardiovascular medicine (6) 6
hematology (6) 6
platelet aggregation inhibitors - adverse effects (6) 6
ticagrelor (6) 6
angioplasty, balloon, coronary - methods (5) 5
anticoagulants (5) 5
aspirin (5) 5
blood platelets - drug effects (5) 5
case-control studies (5) 5
cell biology (5) 5
coronary angiography (5) 5
dose-response relationship, drug (5) 5
drug administration schedule (5) 5
heart-failure (5) 5
intervention (5) 5
platelet aggregation - drug effects (5) 5
platelets (5) 5
predictive value of tests (5) 5
pulmonary arterial-hypertension (5) 5
randomized controlled trials as topic (5) 5
scleroderma (5) 5
scleroderma, systemic - complications (5) 5
scleroderma, systemic - mortality (5) 5
stent implantation (5) 5
survival (5) 5
thrombosis (5) 5
ticlopidine - adverse effects (5) 5
time factors (5) 5
acute coronary syndrome - drug therapy (4) 4
aspirin - therapeutic use (4) 4
atrial-fibrillation (4) 4
blood platelets (4) 4
blood platelets - metabolism (4) 4
cardiovascular diseases - mortality (4) 4
cardiovascular events (4) 4
clinical-outcomes (4) 4
coronary thrombosis - prevention & control (4) 4
echocardiography (4) 4
events (4) 4
guidelines (4) 4
health aspects (4) 4
hemorrhage - chemically induced (4) 4
hypertension (4) 4
involvement (4) 4
medical research (4) 4
medicine & public health (4) 4
myocardial infarction - mortality (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Sibbing, Dirk and Aradi, Dániel and Aradi, Daniel and Jacobshagen, Claudius and Gross, Lisa and Trenk, Dietmar and Geisler, Tobias and Orban, Matthias and Orban, Martin and Hadamitzky, Martin and Merkely, Béla and Kiss, Róbert Gábor and Komócsi, András and Dézsi, Csaba A and Dézsi, Csaba András and Dézsi, András Döme and Holdt, Lesca and Felix, Stephan and Felix, Stephan B and Parma, Zofia and Parma, Radoslaw and Klopotowski, Mariusz and Schwinger, Robert and Schwinger, Robert H G and Rieber, Johannes and Huber, Kurt and Neumann, Franz-Josef and Koltowski, Lukasz and Mehilli, Julinda and Huczek, Zenon and Massberg, Steffen and Lesiak, Maciej and Komosa, Anna and Kowara, Michal and Rymuza, Bartosz and Malek, Lukasz and Veress, Gábor and Lux, Árpád and Papp, Judit and Kovács, Andrea and Amer, Sayour and Ruzsa, Zoltán and Róna, Szilárd and Ili, Renáta and Ungi, Imre and Nagy, Ferenc and Zweiker, Robert and Tóth-Gayor, Gábor and Haller, Paul and von Scheidt, Wolfgang and Blüthgen, Andreas and Leggewie, Stefan and Kreider-Stempfle, Hans Ulrich and Remp, Thomas and Kara, Kaffer and Mügge, Andreas and Wutzler, Alexander and Fichtlscherer, Stephan and Zeiher, Andreas M and Seeger, Florian and Hinterseer, Martin and König, Andreas and Lederle, Susanne and Czepluch, Frauke and Maier, Lars and Schillinger, Wolfgang and Sossalla, Samuel and Hummel, Astrid and Karakas, Mahir and Sydow, Karsten and Rudolph, Tanja and Halbach, Marcel and Gori, Tommaso and Münzel, Thomas and May, Andreas and Gerstenberg, Carsten-Manuel and Pilecky, David and Deichstetter, Markus and Kääb, Stefan and Löw, Anja and Sattler, Stefan and Deuschl, Sabine and Teupser, Daniel and Mudra, Harald and Räder, Thomas and Schütz, Torsten and Vahldiek, Felix and Divchev, Dimitar and Ince, Hüseyin and Nienaber, Christoph A and Radunski, Henning and Boekstegers, Peter and Horstkotte, Jan and Mueller, Ralf and Müller, Karin and Rasp, Oliver and TROPICAL-ACS Investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10104, pp. 1747 - 1757
Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous... 
ELUTING STENTS | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | THERAPY | TICAGRELOR | TREATMENT PATTERNS | PRASUGREL | DIPHOSPHATE RECEPTOR INHIBITOR | OUTCOMES | MYOCARDIAL-INFARCTION PATIENTS | PLATELET REACTIVITY | Myocardial Infarction - epidemiology | Acute Coronary Syndrome - epidemiology | Drug Administration Schedule | Hemorrhage - epidemiology | Humans | Middle Aged | Europe - epidemiology | Male | Prasugrel Hydrochloride - adverse effects | Ticlopidine - analogs & derivatives | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Acute Coronary Syndrome - therapy | Clopidogrel | Female | Stroke - epidemiology | Hemorrhage - chemically induced | Prasugrel Hydrochloride - administration & dosage | Drug Monitoring | Percutaneous Coronary Intervention | Platelet Aggregation Inhibitors - adverse effects | Transluminal angioplasty | Care and treatment | Coronary heart disease | Cardiac patients | Analysis | Anticoagulants | Heart attacks | Blood platelets | Angioplasty | Clinical trials | Acute coronary syndromes | Drug therapy | Patients | Clinical outcomes | Myocardial infarction | Intervention | Medical services | Bleeding | Consortia | Randomization | Motivation | Inhibition | Cerebral infarction | Stroke | Test procedures | Health risks | Thrombosis | Coronary vessels | Biomarkers | Infarction | Cardiovascular diseases | Platelets
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2014, Volume 64, Issue 3, p. 334
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 60, Issue 17, pp. B219 - B219
  Methods Electronic databases were searched to find prospective, randomized, placebo-controlled clinical trials (RCT) that evaluated the clinical impact of... 
Cardiovascular | Internal Medicine | Care and treatment | Anticoagulants (Medicine) | Coronary heart disease | Analysis | Cardiac patients | Anticoagulants | Heart attacks | Acute coronary syndromes | Drug therapy | Angina pectoris
Journal Article
PLoS ONE, ISSN 1932-6203, 2014, Volume 9, Issue 8, p. e104890
Pulmonary arterial hypertension (PH) is associated with high mortality due to right ventricular failure and hypoxia, therefore to understand the mechanism by... 
SIGNALING PATHWAYS | ACTIVATED PROTEIN-KINASE | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | ARTERIAL-HYPERTENSION | RATS | ACUTE LUNG INJURY | SMOOTH-MUSCLE-CELLS | TNF-ALPHA | NF-KAPPA-B | RODENT MODEL | Vasodilator Agents - pharmacology | Vasodilator Agents - therapeutic use | Purines - pharmacology | Rats | NF-kappa B - metabolism | Hypertension, Pulmonary - metabolism | Piperazines - therapeutic use | Sulfonamides - pharmacology | Piperazines - pharmacology | Sildenafil Citrate | Animals | Cell Nucleus - metabolism | MAP Kinase Signaling System - drug effects | Sulfonamides - therapeutic use | Active Transport, Cell Nucleus - drug effects | Lung - drug effects | Chemokines - metabolism | Hypertension, Pulmonary - drug therapy | Lung - metabolism | Purines - therapeutic use | Enzyme Activation | Proto-Oncogene Proteins c-akt - metabolism | Mitogen-Activated Protein Kinases - metabolism | Sildenafil | Cytokines | Health aspects | Phosphotransferases | Analysis | Pulmonary hypertension | Heart | Tissue inhibitor of metalloproteinases | Drinking water | Phosphorylation | Pathogenesis | Interleukin | Monocrotaline | Leukocytes (mononuclear) | AKT protein | Smooth muscle | Right ventricular failure | Activation | Biochemistry | Kinases | Phosphatase | Macrophages | Lung morphology | Proteins | Cell activation | Rodents | Metalloproteinase | Hypertension | NF-κB protein | Pulmonary arteries | Extracellular signal-regulated kinase | MAP kinase | Histology | Inflammation | 1-Phosphatidylinositol 3-kinase | Signaling | Lungs | Protein kinase | γ-Interferon | Morphology | Hypoxia | Interferon | Ventricle | Laboratory animals | Macrophage inflammatory protein | Chemokines | Veins & arteries
Journal Article
American Heart Journal, ISSN 0002-8703, 2010, Volume 160, Issue 3, pp. 543 - 551
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2013, Volume 61, Issue 10, pp. E1922 - E1922
  Primary efficacy endpoints were vascular mortality and definite/probable stent thrombosis (ST), while TIMI major bleeding events were recorded as safety... 
Cardiovascular | Internal Medicine | Coronary heart disease | Cardiac patients | Drug therapy | Acute coronary syndromes | Thrombosis | Mortality
Journal Article
Progress in Cardiovascular Diseases, ISSN 0033-0620, 2015, Volume 58, Issue 5, pp. 483 - 494
Journal Article